Extending the dynamic range of GLP-1 quantitation using the Thermo Scientific Stellar MS
Peptide-based biomarkers and biotherapeutic agents such as GLP-1 present significant challenges to meet quantitative sensitivity requirements. Peptide-based markers tend to be at low dosing/circulating levels in plasma and when analyzed using LC-MSn, ionize into multiple precursor charge states diluting the overall signal used for targeted quantitation.
To meet the experimental requirements for GLP-1 quantitation, the Stellar MS was incorporated into a Thermo Scientific workflow demonstrating extended quantitative sensitivity in plasma matrices. Stellar MS leveraged parallel reaction monitoring (PRM acquisition using MS2 and MS3 acquisition methods depending on sample preparation performed up front. Acquiring data using PRM enabled co-addition of multiple MS2 or MS3 product ions improving S/N measurements at spiking levels below 0.5 ng/mL.
In addition to the LC-MSn analysis, a detailed description of Chromeleon CDS software will be presented on managing the entire experiment, from method optimization to report generation. Key elements will be shown on managing different scan events acquired on Stellar MS for downstream data processing and reporting. Finally, demonstrations of CBMX operation will be shown for study transfer or storage.
Who should attend?
- Lab scientists and technicians working on quantitative analysis
- Pharmaceutical and Biotechnology Professionals
- Clinical Researchers and Biomarker Verification Experts
Presenter: Dr Hao Yang (Thermo Fisher Scientific)
Presenter: Dr. Richard Law
With a background in analytical chemistry and mass spectrometry, Richard is the Product Manager for targeted MS using Chromeleon CDS. He has extensive experience developing applications using LC and GC–MS technologies, especially GC-triple quadrupole MS/MS and HRAM, and has worked across several industry segments.
